Background: The burden of symptoms varies markedly between patients with Chronic 2 Obstructive Pulmonary Disease (COPD) and is only weakly correlated with lung function 3 impairment. While heterogeneity in lung function decline and exacerbations have been 4 previously studied, the extent of heterogeneity in symptoms and the factors associated with this 5 heterogeneity are not well understood. 6 Methods: A sample of the general Canadian population ≥ 40 years with persistent airflow 7 limitation was followed for up to 3 years. Participants reported whether they experienced chronic 8 coughing, phlegm, wheezing, or dyspnea during visits at 18-month intervals. We used mixed-9 effect logistic regression models (separately for each symptom) to assess overall heterogeneity in 1 0 the occurrence of symptoms between individuals, and the proportion of variation in symptom 1 1 burden explained by lung function versus all other clinical characteristics of participants. 1 2 Results: 548 participants (54% male, mean age 67 years) contributed 1,086 visits in total, and 1 3 82% of patients reported at least one symptom during follow-up. There was substantial 1 4 heterogeneity in the individual-specific probabilities for the occurrence of symptoms. This 1 5 heterogeneity was highest for dyspnea and lowest for phlegm (interquartile range of 1 6 probabilities: 0.15-0.77 and <0.01-0.53, respectively). FEV 1 explained 82% of the variation 1 7
We subsequently assessed the proportion of the total heterogeneity in symptoms that 9 8 could be explained by all measured characteristics of individuals. For this, we included patient 9 9 age, sex, body mass index (BMI), ethnicity, number of comorbidities, smoking status, pack-years 1 0 0 of smoking, post-bronchodilator forced expiratory volume in 1 second (FEV 1 ), and diagnosis 1 0 1 status as independent variables in each model (the full models). In order to determine the 1 0 2 variance explained by the independent variables (ie, participants' measured characteristics), we (with all the independent variables), compared to the variance in the random effect of the null 1 0 5 model with no independent variables. 24 We repeated this process using a reduced model with 1 0 6 FEV 1 as the only independent variable (as opposed to the full model) to determine the proportion 1 0 7 of total heterogeneity explained by lung function alone. We conducted sensitivity analyses in which percent predicted FEV 1 and GOLD grade 1 0 9
were used in place of FEV 1 as indicators of lung function (collinearity prevented these variables 1 1 0 from being included in the model at the same time). Seasonality was not included in the main 1 1 1 analysis because the recall period was >1 year and therefore spanned all seasons; however, 1 1 2 season was assessed in a sensitivity analysis to account for the possibility that patients were more 1 1 3 likely to recall their recent symptom burden (which could be affected by the current season). All 1 1 4 analyses were performed in SAS (version 9.4, 2016). The characteristics of participants are shown in Table 1 . There were 1,086 visits from 548 1 1 9 participants in the final sample (54% male, mean age 67 years). 92% of participants had mild to 1 2 0 moderate disease (grade I-II), 7% had severe disease (grade III), and 1% had very severe disease 1 2 1 (grade IV) as measured by GOLD grades. 2 74% of participants with persistent airflow limitation 1 2 2 on spirometry had not been previously diagnosed. The average follow-up time was 18 months; 1 2 3 39% of participants underwent only one study visit, and 37% of participants were assessed at 1 2 4 three study visits. The characteristics of the subset of the data used to analyze dyspnea and any 1 2 5 symptoms were very similar (Supplementary Material, Table 1 ). Most participants did not report having cough, phlegm, wheeze, or dyspnea at each study visit, 1 3 0 but only 18% of participants were completely asymptomatic throughout the study period. The 1 3 1 asymptomatic participants tended to have mild airflow obstruction (mean of 89% predicted 1 3 2 FEV 1 , 16% SD). The proportion of patients that reported a given symptom at least once during 1 3 3 follow-up ranged from 38% for phlegm (the least common symptom) to 56% for dyspnea (the 1 3 4 most common symptom). Symptoms were generally stable within participants: 66% of 1 3 5 participants reported the same level of cough throughout their follow-up (the least stable 1 3 6 symptom), and 75% for phlegm (the most stable symptom). There was substantial variation in the individual-specific probabilities for the occurrence 1 3 8 of symptoms (Figure 1) . The median probabilities of an individual experiencing cough, wheeze, 1 3 9 and dyspnea were 0.36, 0.34, and 0.44, respectively. In contrast, the median probability of The logistic regression models revealed relatively consistent associations between patient and 1 4 8 disease characteristics and the presence of cough, phlegm, wheeze, dyspnea and any symptoms. per 100 mL increase in FEV 1 0.83, 95% CI 0.77-0.88), and least strongly associated with the 1 5 5 presence of cough (OR 0.94, 95% CI 0.90-0.98). These results were similar when lung function 1 5 6 was assessed as percent predicted FEV 1 or GOLD grade in sensitivity analyses (results not 1 5 7 shown). Higher pack-years of smoking, BMI, and a previous diagnosis of COPD were all 1 5 8 associated with an increased odds of reporting most symptoms. Males were more likely than 1 5 9 females to report the presence of cough (OR 2.12, 95% CI 1.18-3.81), phlegm (OR 6.95, 95% CI The proportion of between-individual variation in the occurrence symptoms that could be 1 6 8 attributed to participants' measured characteristics (all independent variables in the full models) 1 6 9 was 21%, 86%, <1%, 44%, and 92%, for cough, phlegm, wheeze, dyspnea, and any symptoms, 1 7 0 respectively ( Table 2 ). The proportion of variation explained by FEV 1 alone ranged from 0% 1 7 1 (for wheeze) to 82% (for phlegm, Table 2 ). We have characterized heterogeneity in the occurrence of respiratory symptoms between patients 1 7 7 with persistent airflow limitation and assessed the extent to which commonly measured patient moderate COPD, and only 26% of them having been diagnosed with COPD. Dyspnea was the 1 8 2 most common symptom, followed by cough and wheeze. Individual-specific probabilities for the 1 8 3 occurrence of symptoms were highly variable between individuals and for different symptoms. The interquartile range of probabilities was the largest for dyspnea and wheeze, indicating or 1 (visible in Figure 1 as a higher density of points at the edges of the plot). In contrast, the 1 8 8 individual-specific probabilities for cough, wheeze, and dyspnea were more evenly spread across 1 8 9 the range of possible values. This indicates that phlegm is more stable in nature, and that 1 9 0 individuals who do not currently have phlegm are unlikely to report it in the future. Indeed, a 1 9 1 pan-European study reported that daily and weekly variability in dyspnea, wheeze, and cough 1 9 2 were higher than that for phlegm. 25 Our findings extend these observations on symptom 1 9 3 variability within individuals to variability between individuals in the occurrence of symptoms. As a result, tools for assessing COPD severity that involve the measurement of symptoms (such 1 9 5 as the GOLD ABCD assessment tool) 2 , are likely to be more or less variable over time, 1 9 6 depending on the symptom measured. The proportion of heterogeneity explained by the measured characteristics of participants Although lung function has traditionally been regarded as the primary driver of 2 0 8 respiratory symptoms, 28 we found that FEV 1 explained the majority of between-individual 2 0 9 variation in only the occurrence of phlegm, although it explained a substantial minority of 2 1 0 variation in dyspnea and any symptoms. This finding is in line with the observation of high 2 1 1 symptom variability within levels of disease severity, 29 and high short-term variability in 2 1 2 symptoms that is not due to changes in lung function. 4, 12 Our results extend these previous 2 1 3 studies by examining the role of FEV 1 in each symptom individually. They suggest that lung 2 1 4 function is the primary driver of the occurrence of phlegm, an important but not dominant driver 2 1 5 of the occurrence of dyspnea and any symptoms, but it explains very little between-individual 2 1 6 variation in the occurrence of cough and wheeze. In addition to analyzing heterogeneity in symptoms, we documented associations 2 1 8 between symptoms and age, sex, BMI, smoking pack-years, FEV 1 , and a previous diagnosis of 2 1 9 COPD. In particular, we observed substantial sex-based differences in the reporting of all 2 2 0 symptoms apart from dyspnea. Controlled for disease severity, smoking history, and other 2 2 1 variables, male patients were over three times more likely to be symptomatic, and seven times 2 2 2 more likely to report experiencing phlegm. Whether this is a biological phenomenon, or due to 2 2 3 gender-related differences in the experience of symptoms, 30 remains to be further assessed. regressions describe the relation between patient and disease characteristics and the presence of a 2 2 7 symptom for an average participant. Our use of a random effect term in our models enabled us to 2 2 8 extend these results by describing the extent to which these population-level associations apply 2 2 9 to a given individual. We found that variation between individuals in the presence of phlegm and 2 3 0 any symptoms was very well described by these population-level associations, but this was not 2 3 1 the case for wheeze and cough (and somewhat the case for dyspnea). The assessment of variation 2 3 2 at an individual-level is critical to fully characterizing heterogeneity in the natural history of of patients with mild-moderate COPD, a population that is often underrepresented in large cohort 2 3 9 studies. The population-based nature of the study makes it a better source for studying disease 2 4 0 heterogeneity than clinical cohorts. However, this study also has several limitations. Patients from all participants prior to study entry. Competing interests: The authors declare that they have no competing interests. The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is currently funded by the BMI: Body Mass Index, FEV 1 : Forced Expiratory Volume in 1 second
Figure 1
The distribution of individual-specific probabilities* of the occurrence of symptoms.
The box spans the lower and upper quartiles (25%-75%) of individuals around the median (blue line).
*Individual random effects are drawn from a normal distribution with a mean of 0 and standard deviation of the fitted random effects. The statistics shown by the boxes were determined from 1000 repetitions for each individual, and the points show the results of one repetition.
Figure 2
Odds ratios for the associations between independent variables and the presence of a) cough, b) phlegm, c) wheeze, and d) dyspnea.
Figure 3
Odds ratios for the associations between independent variables and the presence of any symptoms.
